Recording of non-operating expenses and extraordinary loss
AXEL MARK INC. and its consolidated subsidiary アクセルメディカ株式会社
Share issuance costs associated with the issuance of new shares through a third-party allotment. The result of a careful assessment of the recoverability of loans to アクセルメディカ株式会社
¥5 million in share issuance costs (non-operating expenses) and a ¥13 million provision for doubtful accounts (extraordinary loss in the standalone financial statements; eliminated in the consolidated financial statements)
The consolidated accounting period for the third quarter of the fiscal year ending September 2026
Reflected in the Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending September 2026 [Japanese GAAP], released today
| Item | Details |
|---|---|
| Event name | Recording of non-operating expenses and extraordinary loss |
| Date of occurrence | The consolidated accounting period for the third quarter of the fiscal year ending September 2026 (specific date of occurrence: Not disclosed) |
| Subject Entity | AXEL MARK INC. and its consolidated subsidiary アクセルメディカ株式会社 |
| Cause | Share issuance costs associated with the issuance of new shares through a third-party allotment. The result of a careful assessment of the recoverability of loans to アクセルメディカ株式会社 |
| Amount of Impact on Business Performance | ¥5 million in share issuance costs (non-operating expenses) and a ¥13 million provision for doubtful accounts (extraordinary loss in the standalone financial statements; eliminated in the consolidated financial statements) |
| Accounting period in which recognized | The consolidated accounting period for the third quarter of the fiscal year ending September 2026 |
| Impact on Earnings Forecast | Reflected in the Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending September 2026 [Japanese GAAP], released today |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The share issuance costs arose from the issuance of new shares through a third-party allotment announced on 29 May 2026. The provision for doubtful accounts was recorded following a careful assessment of the recoverability of loans to アクセルメディカ株式会社.